98%
921
2 minutes
20
miRNAs circulating in whole serum and HBsAg-particles are differentially expressed in chronic hepatitis B (CHB) and HBeAg-negative-HBV infection (ENI); their profiles are unknown in chronic hepatitis D (CHD). Serum- and HBsAg-associated miRNAs were analyzed in 75 subjects of 3 well-characterized groups (CHB 25, CHD 25, ENI 25) using next-generation sequencing (NGS). Overall miRNA profiles were consonant in serum and HBsAg-particles but significantly different according to the presence of hepatitis independently of Hepatitis D Virus (HDV)-co-infection. Stringent (Bonferroni Correction < 0.001) differential expression analysis showed 39 miRNAs upregulated in CHB vs. ENI and 31 of them also in CHD vs. ENI. miRNA profiles were coincident in CHB and CHD with only miR-200a-3p upregulated in CHB. Three miRNAs (miR-625-3p, miR-142-5p, and miR-223-3p) involved in immune response were upregulated in ENI. All 3 hepatocellular miRNAs of MiR-B-Index (miR-122-5p, miR-99a-5p, miR-192-5p) were overexpressed in both CHB and CHD patients. In conclusion, CHD and CHB patients showed highly similar serum miRNA profiling that was significantly different from that of individuals with HBeAg-negative infection and without liver disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675264 | PMC |
http://dx.doi.org/10.3390/v15112257 | DOI Listing |
J Formos Med Assoc
September 2025
Department of Oncology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, 315000, China. Electronic address:
Clinics (Sao Paulo)
September 2025
Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil.
Introduction: Conventional mortality statistics that concentrate only on the underlying cause of death may offer a limited view of the complexity of this condition and not fully capture the true extent of mortality from hepatitis C.
Objective: To describe and analyze deaths due to chronic hepatitis C (CHC) in Brazil, as both a underlying and multiple cause of death, from 2000 to 2019.
Methods: This ecological study used data extracted from the Mortality Information System and descriptively analyzed causes of death and sociodemographic variables for the deceased.
J Viral Hepat
October 2025
Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype-specific to pan-genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines. This study examined trends in DAA dispensing in light of evolving treatment regimens.
View Article and Find Full Text PDFLiver Int
October 2025
Department of Pediatrics and Clinical Research Center, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Background And Aims: Sofosbuvir (SOF) plus daclatasvir (DCV) is a primary chronic hepatitis C virus (HCV) treatment in low- and middle-income countries. WHO guidelines recommend a half-adult dose for children (14-25 kg) based on pharmacokinetic modelling, requiring clinical validation. We evaluated the pharmacokinetics, safety, efficacy and acceptability of DCV (30 mg) and SOF (200 mg) in children weighing 14 to < 17 kg and 17-35 kg.
View Article and Find Full Text PDFAliment Pharmacol Ther
September 2025
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.